TARS
NasdaqTARSUS PHARMACEUTICALS, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$57.0M
2021
$25.8M
2022
$17.4M
2023
$183.0M
2024
$451.4M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$451.4M
Net Income$-66.0M
Gross Profit—
Oper Income$-71.0M
EPS (dil)$-1.59
Rev/sh$10.49
FCF/sh$-0.52
Book/sh$7.98
Gross M—
Oper M-15.7%
Profit M-14.6%
FCF M-4.9%
ROE-19.2%
ROA-11.7%
ROIC-31.9%
R&D/Rev14.3%
Rev Y/Y146.7%
Rev 3Y CAGR159.5%
EPS Y/Y48.2%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh$0.00
Shs Chg Y/Y+11.1%
Current Ratio3.85
Quick Ratio3.82
Debt/Eq0.21
Int Coverage-7.9×
Net Debt$113.8M cash
Total Debt$72.4M
Cash & Eq$186.2M
Total Assets$562.2M
Oper CF$-12.5M
Capex$9.9M
Free CF$-22.3M
Buybacks—
Equity$343.4M
Liabilities$218.7M
Shs Outstand0.04B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $57.0M | $25.8M | $17.4M | $183.0M | $451.4M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-12.2M | $-62.7M | $-143.2M | $-120.6M | $-71.0M |
| Net Income | $-13.8M | $-62.1M | $-136.0M | $-116.0M | $-66.0M |
| Diluted EPS | $-0.67 | $-2.52 | $-4.62 | $-3.07 | $-1.59 |
| Operating Cash Flow | $3.7M | $-49.0M | $-117.5M | $-83.0M | $-12.5M |
| Free Cash Flow | $3.2M | $-49.5M | $-119.0M | $-84.6M | $-22.3M |
COMMUNITY · $TARS0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.